See more : Shenzhen Cereals Holdings Co., Ltd. (000019.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Krystal Biotech, Inc. (KRYS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Krystal Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kingfa Sci. & Tech. Co., Ltd. (600143.SS) Income Statement Analysis – Financial Results
- PT Sumi Indo Kabel Tbk (IKBI.JK) Income Statement Analysis – Financial Results
- Tainan Enterprises Co.,Ltd (1473.TW) Income Statement Analysis – Financial Results
- Beasley Broadcast Group, Inc. (BBGI) Income Statement Analysis – Financial Results
- Capcom Co., Ltd. (CCOEF) Income Statement Analysis – Financial Results
Krystal Biotech, Inc. (KRYS)
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.70M | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 |
| Cost of Revenue | 3.09M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| Gross Profit | 47.61M | -4.05M | -2.77M | -1.85M | -974.00K | 886.00K | -23.00K | -2.00K |
| Gross Profit Ratio | 93.90% | 0.00% | 0.00% | 0.00% | 0.00% | 86.27% | 0.00% | 0.00% |
| Research & Development | 46.43M | 42.46M | 27.88M | 17.94M | 15.62M | 7.76M | 3.21M | 741.00K |
| General & Administrative | 0.00 | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 98.40M | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Other Expenses | 12.50M | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 157.33M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Cost & Expenses | 147.93M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Interest Income | 22.62M | 5.22M | 197.00K | 832.00K | 2.99M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 5.22M | 1.49M | 0.00 | 0.00 | 1.03M | 3.15M | 7.00K |
| Depreciation & Amortization | 5.01M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| EBITDA | 17.90M | -145.20M | -65.31M | -30.32M | -18.11M | -10.75M | -4.63M | -1.14M |
| EBITDA Ratio | 35.31% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.54% | 0.00% | 0.00% |
| Operating Income | -109.73M | -145.20M | -68.28M | -33.00M | -22.08M | -11.92M | -4.77M | -1.14M |
| Operating Income Ratio | -216.43% | 0.00% | 0.00% | 0.00% | 0.00% | -1,160.27% | 0.00% | 0.00% |
| Total Other Income/Expenses | 122.62M | 5.22M | -1.30M | 832.00K | 2.99M | 1.03M | -3.15M | -7.00K |
| Income Before Tax | 12.90M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Income Before Tax Ratio | 25.44% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| Income Tax Expense | 1.97M | 34.05M | 2.73M | 1.64M | 576.14K | -20.14K | 0.00 | 0.00 |
| Net Income | 10.93M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Net Income Ratio | 21.56% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| EPS | 0.40 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| EPS Diluted | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| Weighted Avg Shares Out | 27.15M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
| Weighted Avg Shares Out (Dil) | 27.75M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
Why Shares of Krystal Biotech Are Rising Monday
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
Krystal Biotech stock rises after FDA approves treatment for rare skin disease
U.S. FDA approves Krystal Biotech's skin disorder gene therapy
Krystal Biotech: 2 Potential Regulatory Approvals To Carry It Forward
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
Krystal Biotech: Reached My Price Target, Waiting For A Drop
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
Krystal Biotech: A Buy For Growth Potential
Source: https://incomestatements.info
Category: Stock Reports